A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)
Jennifer L. Crombie(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Josie Montegaard(Dana-Farber Cancer Institute), Erin M. Parry(Broad Institute), Shruti Bhandari(Eastern Maine Medical Center), Philippe Armand(Harvard University), Christine E. Ryan(Dana-Farber Cancer Institute), Alvaro J. Alencar(University of Miami), Jacob D. Soumerai(Harvard University), David C. Fisher(Dana-Farber Cancer Institute), Celeste Carey(Dana-Farber Cancer Institute), Aaron Zou(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Samantha Normilus(Dana-Farber Cancer Institute), Yue Ren(Dana-Farber Cancer Institute)
Cited by 6
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890